Jackie Fouse has assembled her executive team at Dermavant and bagged her 5th drug for a beefed up pipeline of skin therapies.
The biotech, part of Vivek Ramaswamy’s network of companies at Roivant, recruited GlaxoSmithKline’s dermatology R&D chief David Rubinstein as chief scientific officer. Rubinstein earlier had worked at Duke. Richard Peterson, formerly at Medicis, has joined as CFO. Ariel Jasie, former CBO at Codiak BioSciences, came on board in the same role, with Chris Van Tuyl joining as general counsel.
Fouse bagged the newly dubbed RVT-504 from TheraVida. The drug — a pill that combines the muscarinic antagonist oxybutynin with the muscarinic agonist pilocarpine — is designed to treat excessive sweating. No terms were disclosed.
Fouse joined Ramaswamy’s group last July after stepping aside as president and COO at Celgene.
Image: Ariel Jasie and David Rubenstein.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.Free Subscription